CTEcells is under clinical development by CTE Biologics and currently in Phase II for Chronic Traumatic Encephalopathy (CTE). According to GlobalData, Phase II drugs for Chronic Traumatic Encephalopathy (CTE) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CTEcells LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CTEcells overview
The therapeutic candidate is under development for the treatment of chronic traumatic encephalopathy. It comprises of CTEcells allogeneic umbilical cord mesenchymal stem cells. The therapeutic candidate is administered through intravenous (IV) route.
It was also under development for the treatment of traumatic brain injury (TBI).
CTE Biologics overview
CTE Biologics, a subsidiary of Therapeutic Solutions International Inc, engaged in research and development of jadicell universal adult stem cells based treatments for chronic traumatic encephalopathy disease. The company is headquartered in New Castle, Delaware, the US.
For a complete picture of CTEcells’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
